|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Warfarin dose related toapolipoprotein E ( APOE) genotype 显示文摘 | Kohnke H Sorlin K Granath G | 2005 | Eur J Clin Pharmacol2005，，： | 1 |
| 2 | Comparison of resin-contai- ning Bactec Plus Aerobic/F * medium with conventional methods for culture of normally sterile body fluids 显示文摘 | Sorlin P Mansoor I Dagyaran C | 2000 | J Med Microbiol2000，49，9： | 1 |
| 3 | Effect of long-term treatment with platelet-activating factor of IL-1 and IL-2 prodution by rat spleen cells显示文摘 | Henane S Sorlin B | 1990 | J Immunol1990，145，： | 1 |
| 4 | Warfarin sensitivity related to CYP2C9,CYP3A5,ABCB1 (MDR1) and other factors显示文摘 | Wadelius M Sorlin K Wallerman O Karlsson J Yue QY Magnusson PK | 2004 | Pharmacogenomics J2004，4，： | 1 |
| 5 | Comparison of resin-containing BACTECTM plus Aerobic/F* medium with conventional methods for culture of normally sterile body fluids 显示文摘 | Sorlin P Mansoor I Dagyaran C | 2000 | J Med Microbiol2000，49，9： | 1 |
| 6 | Warfarin dose related to apolipoprotein E (APOE) genotype显示文摘 | Kohnke H Sorlin K Granath G Wadelius M | 2005 | Eur J Clin Pharmacol2005，61，56： | 1 |
| 7 | Warfarin sensitivity related to CYP2C9 ,CYP3A5 ,ABCB1 ( MDR1 )and other factors显示文摘 | Wadelius M Sorlin K Wallerman O | 2004 | Pharmacogenomics J2004，4，1： | 1 |
| 8 | Warfarin dose related to apolipopretein E ( APOE ) genotype 显示文摘 | Kohnke H Sorlin K Granath G | 2005 | Eur J Clin Pharmaeol2005，61，5： | 1 |
| 9 | Warfarin sensitivity related to CYP2C9,CYP3A5,ABCB1 (MDR1) and other factors显示文摘 | Sorlin K Wallerman O | 2004 | Pharmacogenomics J2004，4，1： | 1 |
| 10 | Warfarin dose related to apolipoprotein E (APOE) genotype显示文摘 | Kohnke H Sorlin K Granath G Wadelius M | 2005 | Clin Pharmacol J2005，61，： | 1 |
| 11 | Wartarin sensitivity related to CYP2C9, CYP3A5, ABCB1 ( MDR1 ) and other factors显示文摘 | Wadelius M Sorlin K Wallerman O | 2004 | Pharmacogenomics J2004，4，1： | 1 |
| 12 | Comparison of resin-containing Bactec Plus Aerobic /F medium with conventional methods for culture of normally sterile body fluids显示文摘 | Sorlin P Mansoor I Dagyaran C | | 0，，09： | 1 |
| 13 | Warfarin dose related to apolipoprotein E (APOE) genotype显示文摘 | Sorlin K Granath G | 2005 | Eur J Clin Pharmacol2005，61，56： | 1 |
| 14 | Warfarin dose related to apolipoprotein E (APOE) genotype 显示文摘 | Kohnke H Sorlin K Granath G | 2005 | Eur J Clin Pharmacol2005，61，56： | 1 |
| 15 | Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDRI) and other factors 显示文摘 | Wadelius M Sorlin K Wallerman O | 2004 | Pharmacogenomics J2004，4，1： | 1 |
| 16 | Warfarin dose related to apolipoprotein E (APOE) genotype显示文摘 | Kohnke H Sorlin K Granath G | 2005 | Eur J Clin Pharmacol2005，61，： | 1 |
| 17 | Warfarin dose related to apolipoprotein E (APOE) genotype 显示文摘 | KOHNKE H SORLIN K GRANATH G | 2005 | Eur J Clin Pharmacol2005，61，56： | 1 |
| 18 | Comparison of resin- containing BACTEC^TM plus Aerobic/F^* medium with conventional methods for culture of normally sterile body fluids 显示文摘 | Sorlin P Mansoo r I Dagyaran C | 2000 | J M ed Microbiol2000，49，9： | 1 |
| 19 | Warfarin dose related to apolipoprotein E (APOE) genotype显示文摘 | Kohnke H Sorlin K Granath G | | 0，，5： | 1 |
| 20 | Warfarin sensitivity related to CYP2C9, CYP3AS, ABCB1 (MDR1) and other factors显示文摘 | Wadelius M Sorlin K Wallerman O | 2004 | Pharmacogenomics J2004，4，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员